The has announced seventy-five grants totaling $40.3 million.
The grants will fund research aimed at finding better treatments and cures for patients with leukemia, lymphoma, myeloma, and other blood cancers. In the area of immunotherapy, LLS awarded grants totaling $11 million, including $2.4 million to the in support of a collaborative translational research initiative that will provide research centers at , the , , and with grants of $600,000 for research related to the immune system in patients with leukemia and lymphoma.
LLS also awarded grants in support of precision medicine projects, including a total of $5.5 million to eleven academic centers working to advance treatments for acute myeloid leukemia (AML), and $600,000 to for a study of targeted approaches for the treatment of a rare blood cancer called monoclonal gammopathy of undetermined significance, which can be a precursor to multiple myeloma. The grants also include support for LLS's , the first collaborative precision medicine trial involving a blood cancer.
"LLS is leading the way by investing in cutting-edge research and clinical trials with the most promise of yielding cures and improving survival and the quality of life for blood cancer patients," said LLS president and CEO Louis J. DeGennaro. "In our sixty-seven-year history, we have invested more than $1 billion in research to advance breakthrough therapies and cures, and many of our successes in the blood cancers are now helping patients with other cancers and chronic diseases."